Golden
PhagoMed Biopharma

PhagoMed Biopharma

A biotechnology company developing phage therapies to replace ineffective antibiotics.

PhagoMed Biopharma is a biotechnology company developing phage therapies to replace ineffective antibiotics that is headquartered in Vienna, Austria and was founded in 2017 by Alexander Belcredi and Burkhard Wippermann.



Products

PM398

PM398 is a phage therapy designed to destroy multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA).



Funding

Seed

On August 28, 2018 PhagoMed Biopharma completed a seed funding round with €4M in funding from from undisclosed investors. 

Timeline

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link

PhagoMed - Virtual Tour (aws Phoenix video in English)

February 13, 2019

PhagoMed Biopharma uses technology to find alternative to antibiotics

January 8, 2019

PhagoMed PM398 in action

November 13, 2018

Companies

Company
CEO
Location
Products/Services









References